메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Ji Yun Lee (Seoul National University Bundang Hospital) Jin Ho Paik (Seoul National University Bundang Hospital) Koung Jin Suh (Seoul National University Bundang Hospital Seongnam Korea) 김지원 (분당서울대학교병원) Se Hyun Kim (Seoul National University Bundang Hospital) Jin Won Kim (Seoul National University Bundang Hospital, Seongnam, Korea) Yu Jung Kim (Seoul National University Bundang Hospital) Keun-Wook Lee (Seoul National University Bundang Hospital Seongnam Korea) Jee Hyun Kim (Seoul National University Bundang Hospital) Soo-Mee Bang (Seoul National University Bundang Hospital) Jong-Seok Lee (Seoul National University Bundang Hospital Seongnam Korea) Jeong-Ok Lee (Department of Internal Medicine Seoul National University Bundang Hospital)
저널정보
대한혈액학회 Blood Research Blood Research Vol.56 No.4
발행연도
2021.12
수록면
285 - 292 (8page)
DOI
10.5045/br.2021.2021073

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background High-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as a consolidation treatment is a promising approach for eligible patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Methods In this retrospective analysis, 22 patients with newly diagnosed PCNSL received chemotherapy with rituximab, methotrexate, procarbazine, and vincristine. Those who showed complete or partial response subsequently received consolidation HDC-ASCT with a thiotepa- based conditioning regimen but did not undergo radiotherapy. Results The PCNSL patients had a median age of 57 years (range, 49?67 yr); of the total patients, 9.1% had a performance status of 2 or higher, and 72.1% had multiple lesions. Approximately 82% of patients received six cycles of induction chemotherapy, which was well tolerated with excellent disease control. The rate of confirmed or unconfirmed complete response increased from 45.5% at the period of interim analysis to 81.8% prior to the initiation of HDC-ASCT. With a median follow-up of 19.6 months (range, 7.5?56.5 mo), the 2-year progression-free survival and overall survival estimates were 84% and 88%, respectively. No treatment-related deaths occurred. Grade 3 toxicity was recorded in 90.9% of the patients after undergoing the HDC-ASCT, and the most common grade 3 adverse event was febrile neutropenia without sepsis. Conclusion The discussed treatment approach is feasible in patients with newly diagnosed PCNSL, yielding encouraging results.

목차

등록된 정보가 없습니다.

참고문헌 (31)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0